Prepulse Inhibition of Startle in Cocaine Dependence - 7

This study has been completed.
Sponsor:
Collaborator:
New York MDRU
Information provided by:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00015249
First received: April 18, 2001
Last updated: November 3, 2005
Last verified: June 1998
  Purpose

The purpose of this study is to assess the effects of chronic cocaine use on the acoustic startle response and on gating of this response in humans.


Condition Intervention Phase
Cocaine-Related Disorders
Substance-Related Disorders
Drug: Amantadine
Phase 1

Study Type: Interventional
Study Design: Masking: Double-Blind
Primary Purpose: Diagnostic
Official Title: Prepulse Inhibition of Startle in Cocaine Dependence (Human)

Resource links provided by NLM:


Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Percent prepulse inhibition
  • Cocaine assessment

Estimated Enrollment: 0
Study Start Date: February 1997
Detailed Description:

The objective of this study is to assess the effects of chronic cocaine use on the acoustic startle response and on gating of this response in humans.

  Eligibility

Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Cocaine dependence. Male. Right handed. Negative urine for cocaine

Exclusion Criteria:

Positive urine for cocaine. History of head trauma. Significant medical disease.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00015249

Locations
United States, New York
New York MDRU
New York, New York, United States, 10010
Sponsors and Collaborators
New York MDRU
Investigators
Principal Investigator: John Rotrosen, M.D. New York MDRU
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00015249     History of Changes
Other Study ID Numbers: NIDA-5-0013-7, Y01-5-0013-7
Study First Received: April 18, 2001
Last Updated: November 3, 2005
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Cocaine-Related Disorders
Substance-Related Disorders
Mental Disorders
Amantadine
Antiparkinson Agents
Anti-Dyskinesia Agents
Central Nervous System Agents
Therapeutic Uses
Pharmacologic Actions
Antiviral Agents
Anti-Infective Agents
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents

ClinicalTrials.gov processed this record on July 24, 2014